Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:NXENNYSE:PTNNASDAQ:SCNINASDAQ:SPRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNXENNexien BioPharma$0.01$0.01$0.00▼$0.05$686K-0.7914,596 shsN/APTNPalatin Technologies$0.09-44.6%$0.00$0.09▼$2.48$2.45M0.942.28 million shs14.57 million shsSCNIScinai Immunotherapeutics$2.83-1.0%$2.66$1.90▼$8.92$2.80M2.23278,874 shs666 shsSPRBSpruce Biosciences$0.06-4.1%$0.18$0.06▼$0.76$2.55M2.49726,797 shs24,865 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNXENNexien BioPharma0.00%0.00%+7.78%+38.57%-53.81%PTNPalatin Technologies0.00%0.00%-55.19%+9,409,900.00%+9,409,900.00%SCNIScinai Immunotherapeutics-3.71%-0.67%+31.67%-18.18%-17.70%SPRBSpruce Biosciences-4.13%-8.35%-53.40%-85.62%-91.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNXENNexien BioPharmaN/AN/AN/AN/AN/AN/AN/AN/APTNPalatin TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ASCNIScinai Immunotherapeutics0.2795 of 5 stars0.03.00.00.00.02.50.0SPRBSpruce Biosciences1.8664 of 5 stars3.03.00.00.00.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNXENNexien BioPharma 0.00N/AN/AN/APTNPalatin Technologies 0.00N/AN/AN/ASCNIScinai Immunotherapeutics 0.00N/AN/AN/ASPRBSpruce Biosciences 2.00Hold$2.173,487.20% UpsideCurrent Analyst Ratings BreakdownLatest NXEN, SPRB, SCNI, and PTN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025SPRBSpruce BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$1.50 ➝ $0.50(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNXENNexien BioPharmaN/AN/AN/AN/A($0.01) per shareN/APTNPalatin Technologies$350K6.99N/AN/AN/A∞SCNIScinai Immunotherapeutics$658K4.30N/AN/A($9.84) per share-0.29SPRBSpruce Biosciences$4.91M0.52N/AN/A$1.88 per share0.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNXENNexien BioPharma-$240KN/A0.00∞N/AN/AN/A-3,415.76%N/APTNPalatin TechnologiesN/A-$1.55N/A∞N/AN/AN/AN/AN/ASCNIScinai Immunotherapeutics-$6.50M-$9.57N/A∞N/AN/AN/A-30.48%7/1/2025 (Estimated)SPRBSpruce Biosciences-$47.92M-$1.32N/AN/AN/A-555.23%-62.10%-47.49%8/11/2025 (Estimated)Latest NXEN, SPRB, SCNI, and PTN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q4 2024SCNIScinai ImmunotherapeuticsN/A-$10.40N/A-$10.40N/A$0.21 million4/15/2025Q4 2024SPRBSpruce Biosciences-$0.20-$0.57-$0.37-$0.57$0.50 million$0.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNXENNexien BioPharmaN/AN/AN/AN/AN/APTNPalatin TechnologiesN/AN/AN/AN/AN/ASCNIScinai ImmunotherapeuticsN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNXENNexien BioPharmaN/AN/A0.01PTNPalatin TechnologiesN/AN/AN/ASCNIScinai Immunotherapeutics0.061.161.16SPRBSpruce Biosciences0.015.365.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNXENNexien BioPharmaN/APTNPalatin Technologies11.50%SCNIScinai Immunotherapeutics58.41%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipNXENNexien BioPharma30.60%PTNPalatin Technologies7.10%SCNIScinai Immunotherapeutics60.90%SPRBSpruce Biosciences9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNXENNexien BioPharma470.77 million49.12 millionNot OptionablePTNPalatin Technologies3026.01 millionN/AN/ASCNIScinai Immunotherapeutics201.00 million334,000Not OptionableSPRBSpruce Biosciences2042.23 million37.54 millionOptionableNXEN, SPRB, SCNI, and PTN HeadlinesRecent News About These CompaniesSpruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacksMay 7, 2025 | investing.comSpruce Biosciences Inc Ordinary SharesMay 6, 2025 | morningstar.comSpruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 6, 2025 | finance.yahoo.comSpruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease AssetApril 28, 2025 | biospace.comSpruce halves head count, narrowing focus to get ex-BioMarin drug to FDAApril 28, 2025 | fiercebiotech.comSpruce Biosciences (SPRB) Receives a Hold from RBC CapitalApril 17, 2025 | markets.businessinsider.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call TranscriptApril 17, 2025 | insidermonkey.comSpruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)April 15, 2025 | standard-journal.comWith BioMarin deal, Spruce Biosciences hits reset on rare-disease drugApril 15, 2025 | bizjournals.comSpruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)April 15, 2025 | seekingalpha.comSpruce Biosciences reports delayed annual filingApril 3, 2025 | investing.comSpruce Biosciences Inc (SPRB) Stock: Understanding Its Underlying ValueFebruary 5, 2025 | bovnews.comHold Rating for Spruce Biosciences Amid Clinical Setbacks and Strategic UncertaintiesDecember 16, 2024 | markets.businessinsider.comSpruce Biosciences (SPRB) Upgraded to Buy: Here's WhyDecember 13, 2024 | zacks.comJMP Securities Downgrades Spruce Biosciences (SPRB)December 12, 2024 | msn.comSpruce saws off only drug after 2nd hyperplasia fail, leaving biotech's direction in doubtDecember 11, 2024 | fiercebiotech.comSpruce Biosciences Downgraded to Hold Amid Unmet Clinical Trial Endpoints and Strategic ReevaluationDecember 11, 2024 | markets.businessinsider.comWhat’s Driving Spruce Biosciences Inc (SPRB) Stock’s 0.22% Surge Over the Past Month?December 11, 2024 | bovnews.comOppenheimer Downgrades Spruce Biosciences (SPRB)December 11, 2024 | msn.comSpruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAHDecember 11, 2024 | finance.yahoo.comMedia Sentiment Over TimeNXEN, SPRB, SCNI, and PTN Company DescriptionsNexien BioPharma OTCMKTS:NXEN$0.0097 0.00 (0.00%) As of 05/21/2025Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.Palatin Technologies NYSE:PTN$0.09 -0.08 (-44.65%) As of 05/7/2025Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.Scinai Immunotherapeutics NASDAQ:SCNI$2.83 -0.03 (-1.05%) As of 09:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.Spruce Biosciences NASDAQ:SPRB$0.06 0.00 (-4.13%) As of 05/22/2025 03:08 PM EasternSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Cathie Wood Just Bought a New Stake in Taiwan Semiconductor Stock Super Micro Computer Stock Clears New Path Higher on Saudi Orders Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Why Carnival Could Be the Ultimate Non-Tech Growth Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
